4DIN
4DIN is a Tokyo-based private company providing clinical data anonymization (CoNaxs), analysis (SIMPRESEARCH), and pharmacovigilance (DRiFOs) platforms to Japanese pharmaceutical companies and university hospitals. Its 4DIN Research Network spans 20+ university hospitals covering 13M+ patients.
- Company typePrivate
- Founded2003
- HeadquartersTokyo, Japan
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What 4DIN does
4DIN (株式会社4DIN) is a Tokyo-based private company founded in 2003 (rebranded in 2019 via an MBO of Convergence CT Japan by current CEO Akihiko Takahashi) that provides clinical data anonymization, analysis, and risk management platforms for the Japanese life sciences and medical research market. Its core technology stack centers on three integrated products: SIMPRESEARCH®, a cloud-based clinical information analysis platform that enables researchers to perform BI-tool, R, and Python analytics on anonymized electronic medical record data without acquiring raw datasets; CoNaxs, a clinical data anonymization tool protected by Patent No. 7075063 that uses patented algorithms to preserve temporal dependencies in clinical data while stripping personally identifiable information; and DRiFOs®, a drug risk management system that consolidates adverse event data from PMDA and FDA into a searchable database. The underlying platform is powered by a 4DIN Research Network spanning 20+ university hospitals (including 6 clinical research core hospitals) with access to electronic medical record data for over 13 million patients.
4DIN's business model combines subscription-based platform licensing (SIMPRESEARCH, CoNaxs, DRiFOs) with professional services revenue, including RWE Generation services, Academic Service database research support, and Real World Insight™ statistical browsing. The go-to-market is sales-led and enterprise-focused, targeting Japanese pharmaceutical companies (including named customers Shionogi, Ono, and Daiichi Sankyo), university hospitals, medical device and SaMD developers, CROs, and SMOs. Distribution is primarily direct enterprise sales, supplemented by a strategic partnership with MedPeer for co-development and channel distribution and an IT integration partnership with SCSK Corporation. The company is currently single-geography (Japan) and operates with 11–50 employees from its headquarters in Minato-ku, Tokyo. 4DIN has achieved regulatory-grade data handling credentials, notably ISMS ISO/IEC 27001:2022 certification obtained in December 2024, and has supported publication of over 100 peer-reviewed research papers using its platform.
Recent strategic activity is consistent with a growth-stage private company: a 2026 funding round led by Biz Architects (undisclosed amount) is intended to combine 4DIN's data infrastructure with the investor's AI and management expertise, while a 2022 corporate investment from MedPeer established the strategic real-world data partnership. The leadership team combines deep clinical research and consulting backgrounds, with the chairman having previously led EPS Holdings (now EPS Holdings) and the CFO having prior venture capital experience. The company's research network footprint, anonymization IP, and ISO certification form a credible basis for continued expansion in the Japanese pharma RWE and academic clinical research segments, though the company has not yet disclosed international expansion or significant AI-native product capabilities.
4DIN firmographics
Firmographics- Name
- 4DIN
- Legal name
- 株式会社4DIN
- Website
- https://4din.com
- Company type
- Private
- Founded year
- 2003
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- 4DIN is a Tokyo-based private company providing clinical data anonymization (CoNaxs), analysis (SIMPRESEARCH), and pharmacovigilance (DRiFOs) platforms to Japanese pharmaceutical companies and university hospitals. Its 4DIN Research Network spans 20+ university hospitals covering 13M+ patients.
- Ownership category
- akta.pro rank
4DIN industry classification
Industry- Product category
- Clinical Research Data Analytics and Real-World Evidence Platforms
- NAICS
- Scientific Research and Development Services (5417), Custom Computer Programming Services (541511)
- SIC
- Services-Health Services (8000), Services-Misc Health & Allied Services, Nec (8090)
- akta.pro primary industry
- Real-World Data (RWD) Platforms & Clinical Data Curation (HLACAIAJ)
- akta.pro secondary industries
- De-identification, Tokenization & Privacy-Preserving Data Platforms (HLACAIAK), Clinical & Translational Informatics (Clinical Data Integration/Real-World Data for R&D) (HLAGAJAF), Real-World Data (RWD) / Real-World Evidence (RWE) & Observational Research Platforms (HLACAOAM)
Keywords
Where 4DIN is headquartered
LocationHeadquarters
- HQ city
- Tokyo
- HQ country
- Japan
- HQ region
- Asia
Offices1 record
Markets served
4DIN business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Marketing or Sales, Infrastructure, Operations
Revenue model
- Platform Licensing (SIMPRESEARCH): Cloud-based clinical information analysis platform licensed to medical institutions and pharmaceutical companies for data analysis, research support, and cross-institutional studies.
- Anonymization Services (CoNaxs): Clinical data anonymization services converting medical data into privacy-compliant research-ready datasets.
- RWE Generation Services: Real World Evidence generation services including feasibility surveys, study setup support (contracts, ethics review, protocol creation), statistical analysis, publication support, and patient journey creation for pharmaceutical companies.
- Risk Management Services (DRiFOs): Subscription-based pharmaceutical risk management system providing adverse event database access and signal detection capabilities.
- Academic Services: Database research support services including analysis reports, consulting, study planning, feasibility surveys, data cleaning, aggregation, statistical analysis, and publication support for academic institutions.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Annual | Enterprise pharmaceutical pricing |
Go-to-market motion3 records
Distribution channels3 records
Marketing channels5 records
4DIN product offering
Product offeringCore offering
4DIN provides cloud-based clinical information analysis and anonymization software (SIMPRESEARCH, CoNaxs, DRiFOs) alongside professional services for real-world evidence generation, feasibility studies, statistical analysis, and publication support to pharmaceutical companies, university hospitals, and medical device developers in Japan. Its integrated anonymization-to-analysis workflow leverages a research network of 20+ university hospitals covering 13 million+ patients, enabling privacy-compliant cross-institutional clinical research.
Product overview
4DIN is a medical and life sciences data utilization company offering a multi-product platform architecture built around three core offerings: (1) SIMPRESEARCH® — a cloud-based clinical information analysis platform (臨床情報分析支援プラットフォーム) enabling researchers to perform R/Python analytics on anonymized EHR data across institutions without acquiring raw datasets; (2) CoNaxs — a clinical information anonymization tool with patented algorithms that transforms medical data into research-ready anonymized datasets, used internally within the 4DIN Research Network; and (3) DRiFOs® — a drug risk management system aggregating adverse event data from PMDA/FDA. Additional services include Academic Service (database research support from feasibility through publication), and pharmaceutical-facing services Real World Insight™ and RWE Generation for clinical development, market access, and post-marketing surveillance, all leveraging the 4DIN Research Network spanning 20+ university hospitals with access to 13M++ patient records.
Differentiator
Problem solved
Functional benefit
Products and services
- SIMPRESEARCH® Cloud-based clinical information analysis support platform enabling researchers to perform advanced data analysis using BI tools, R, and Python on anonymized electronic medical record data without obtaining raw datasets. Supports cross-institutional data analysis, intuitive patient search, and publication-ready visualization for pharmaceutical companies and university hospitals.
- CoNaxs Clinical information anonymization tool specialized for medical data, using a patented algorithm to rapidly and easily convert medical data into anonymized datasets that reduce personal identification information while preserving clinical research value. Integrates with SIMPRESEARCH for seamless anonymized analysis workflows.
- Academic Service (アカデミックサービス)
- DRiFOs®
- Real World Insight™
- RWE Generation
Quantifiable outcome
- 100+ research papers supported and published in peer-reviewed journals including Cureus, BMC Geriatrics, PLOS ONE, Clinical Radiology, Scientific Reports, BMJ Open
- +2 more outcomes
Companies that use 4DIN
Customer profileNamed customers12 records
Segments4 records
Ideal customer profiles4 records
4DIN technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration3 records
AI capability1 record
Feature4 records
4DIN partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered supporting and core.
- SCSK Corporation (SCSK株式会社)supportingBusiness partnership agreement for collaborative development and expansion of healthcare data utilization services. SCSK provides IT system development and integration capabilities.
- MedPeer Co., Ltd. (メドピア株式会社)coreMedPeer invested in 4DIN and entered a business partnership for joint development of real-world data utilization services. MedPeer focuses on诊疗データと医師のインサイトデータを用いた製薬企業向けデータ利活用サービスの構築. The partnership combines MedPeer's physician insight data with 4DIN's electronic medical record data capabilities.
- MedPeer Co., Ltd. (メドピア株式会社)coreBusiness partnership agreement for co-development of pharmaceutical company-focused real-world data utilization services. The partnership leverages MedPeer's physician network and insights with 4DIN's data platform capabilities.
Scale indicators6 records
Recent moves6 records
Expansion highlights5 records
4DIN competitors and assessment
Company assessmentDirect peers
- JMDC Inc. Japanese health data analytics company that aggregates claims, DPC, and EHR data to provide real-world data and evidence services to pharmaceutical companies. Closest comparable to 4DIN in domestic RWD/RWE positioning for the Japanese pharma market.
- Medical Data Vision Co., Ltd. (MDV): Japanese company operating one of the largest DPC and EHR databases in Japan, providing real-world data and analytical services to pharma, academia, and government. Direct competitor to 4DIN in hospital-sourced RWD for pharmaceutical customers.
Broad incumbents
- IQVIA: Global leader in clinical research services, RWE, and healthcare data analytics with significant Japan operations. Offers end-to-end RWE solutions that overlap with 4DIN's pharma RWE generation services, though at vastly larger scale.
- TriNetX: Global RWD network used by pharmaceutical companies and academic medical centers for clinical trial feasibility and observational research. Operates a federated network model similar to 4DIN Research Network but at global scale across healthcare organizations.
- EPS Holdings: Japan's largest CRO offering clinical trial, real-world evidence, and post-marketing services. 4DIN's Chairman Tashiro is a former EPS Holdings executive, illustrating the close ecosystem overlap. EPS is a much larger incumbent that could expand its data platform offerings.
- Medidata Solutions (Dassault Systèmes): Clinical trial technology platform offering EDC, CTMS, and increasingly RWD/RWE capabilities. Competes with 4DIN in the clinical development analytics space for pharmaceutical customers, though at much larger scale.
- Veradigm (Allscripts): Healthcare data and analytics provider with deep EHR integrations and life sciences RWD offerings to pharma. Competes in the same healthcare data analytics space as 4DIN, but with US-centric scale and EHR vendor relationships.
- Flatiron Health: RWD and RWE platform focused on oncology, owned by Roche. Provides EHR-derived real-world data and analytical services to pharma similar to 4DIN's pharma offerings, but with deeper oncology specialization and global reach.
Regional players
- Cegedim: European-headquartered healthcare data and CRM company with real-world evidence offerings. Comparable to 4DIN in pharma RWD and anonymization services, but operates primarily in Europe and US rather than Japan.
- Real World Data Co., Ltd. (RWD): Japanese-focused RWD service provider working with university hospital networks to deliver real-world evidence to pharma. Direct competitor in the same Japanese university-hospital data network niche that 4DIN occupies.
Market position
Strengths5 records
Weaknesses4 records
Competitive moat5 records
Key risks5 records
Key highlights6 records
Customer concentration
4DIN social profiles
Digital presence4DIN compliance and trust
Trust signalCompliance1 record
4DIN financial estimates
Financial estimateRevenue estimate
Valuation estimate
4DIN leadership team
Management profileNumber of profiles
Profiles7 records
4DIN funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
4DIN M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about 4DIN
What does 4DIN do?
4DIN provides cloud-based clinical information analysis and anonymization software (SIMPRESEARCH, CoNaxs, DRiFOs) alongside professional services for real-world evidence generation, feasibility studies, statistical analysis, and publication support to pharmaceutical companies, university hospitals, and medical device developers in Japan. Its integrated anonymization-to-analysis workflow leverages a research network of 20+ university hospitals covering 13 million+ patients, enabling privacy-compliant cross-institutional clinical research.
Is 4DIN a public or private company?
4DIN is a private company. It is classified as venture growth investor backed and is currently operating.
When was 4DIN founded?
4DIN was founded in 2003. It employs 11 to 50 people.
Where is 4DIN based?
4DIN is headquartered in Tokyo, Japan, in the Asia region.
How does 4DIN make money?
Five revenue lines are on record. Platform Licensing (SIMPRESEARCH) is the primary driver. The others are anonymization Services (CoNaxs), RWE Generation Services, risk Management Services (DRiFOs) and academic Services.
Who are 4DIN's main competitors?
Direct peers on record are JMDC Inc. and Medical Data Vision Co., Ltd. (MDV). Broad incumbents are IQVIA, TriNetX, EPS Holdings, Medidata Solutions (Dassault Systèmes), Veradigm (Allscripts) and Flatiron Health. Regional players are Cegedim and Real World Data Co., Ltd. (RWD).
Does 4DIN have an API?
No public API is recorded for 4DIN.
What industry is 4DIN in?
4DIN's product category is Clinical Research Data Analytics and Real-World Evidence Platforms. Its primary akta.pro industry code is HLACAIAJ, Real-World Data (RWD) Platforms & Clinical Data Curation, with a secondary code of HLACAIAK, De-identification, Tokenization & Privacy-Preserving Data Platforms. Its NAICS code is 5417 and its SIC code is 8000.